Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 36Prostatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 14Lymphoma 13Rectal Neoplasms 11Lung Neoplasms 11Head and Neck Neoplasms 11Recurrence 10Neoplasms 10Neoplasm Metastasis 9Carcinoma, Hepatocellular 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Leukemia 7Central Nervous System Neoplasms 7Brain Neoplasms 7Multiple Myeloma 6Hyperthermia 6Carcinoma, Intraductal, Noninfiltrating 6Lymphoma, Follicular 5Hodgkin Disease 5Glioblastoma 5Dendritic Cell Sarcoma, Interdigitating 5Congenital Abnormalities 5Colorectal Neoplasms 5

Interventions

Radiotherapy 2Immune Checkpoint Inhibitors 2aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Advanced NSCLC × Radiotherapy × Clear all
NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡